Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00273650 · ClinicalTrials.gov registry record · Phase 2

Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism

A Phase 2 study, sponsored by University of California, San Francisco.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target

NCT00273650 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00273650, a Phase 2 study, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target

Study Summary

We will be testing a specific dietary supplement, methylcobalamin (vitamin B12). Follow-up assessments with our clinical team will take place over the 12-week study period so that we can record any changes in development. The main goal of this study is to determine if subcutaneous injections of vitamin B12 given every three days can positively affect behavior and development in children with autism. Hypothesis: Methylcobalamin injections will improve measures of executive function, speech, and socialization in children with autism, and will be associated with metabolic improvement.

Interventions

  • DRUG methylcobalamin
  • OTHER saline placebo

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2005-07
Est. Completion 2009-08
Phase Phase 2

What the Registry Record Tells You About NCT00273650

The ClinicalTrials.gov registry entry for NCT00273650 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which methylcobalamin is the first listed.

NCT00273650 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00273650 about?

NCT00273650 is a clinical study titled "Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism". We will be testing a specific dietary supplement, methylcobalamin (vitamin B12). Follow-up assessments with our clinical team will take place over the 12-week study period so that we can record any changes in development. The main goal of this study is to determine if subcutaneous injections of vita...

What is the current status of trial NCT00273650?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-07. Estimated completion is 2009-08.

What interventions are being tested in trial NCT00273650?

The interventions under investigation include: methylcobalamin (DRUG), saline placebo (OTHER).

Who is sponsoring clinical trial NCT00273650?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.